Shares of Acceleron Pharma Inc. (NASDAQ:XLRN) traded down 4.2% on Monday . The company traded as low as $31.50 and last traded at $31.58, with a volume of 90,529 shares changing hands. The stock had previously closed at $32.97.

A number of analysts have recently weighed in on the company. Credit Suisse Group AG reiterated a “buy” rating on shares of Acceleron Pharma in a research report on Sunday, July 10th. Leerink Swann reiterated a “buy” rating on shares of Acceleron Pharma in a research report on Sunday, June 12th. Zacks Investment Research downgraded Acceleron Pharma from a “buy” rating to a “hold” rating in a research report on Thursday, April 28th. Oppenheimer Holdings Inc. restated a “buy” rating on shares of Acceleron Pharma in a research report on Sunday, April 17th. Finally, Barclays PLC initiated coverage on Acceleron Pharma in a research report on Wednesday, April 27th. They set an “overweight” rating and a $40.00 price objective for the company. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. Acceleron Pharma has an average rating of “Buy” and a consensus price target of $49.43.

The stock has a 50-day moving average price of $33.70 and a 200 day moving average price of $30.94. The stock’s market capitalization is $1.13 billion.

Acceleron Pharma (NASDAQ:XLRN) last released its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.59) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.50) by $0.09. The business earned $3.20 million during the quarter, compared to analyst estimates of $3.77 million. Acceleron Pharma’s quarterly revenue was down 43.9% compared to the same quarter last year. Equities analysts forecast that Acceleron Pharma Inc. will post ($1.56) earnings per share for the current year.

In other news, CEO John L. Knopf sold 100,000 shares of Acceleron Pharma stock in a transaction on Wednesday, July 6th. The stock was sold at an average price of $33.87, for a total value of $3,387,000.00. Following the completion of the transaction, the chief executive officer now directly owns 147,106 shares in the company, valued at $4,982,480.22. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO John L. Knopf sold 28,022 shares of Acceleron Pharma stock in a transaction on Friday, July 1st. The shares were sold at an average price of $34.72, for a total value of $972,923.84. Following the completion of the transaction, the chief executive officer now owns 147,106 shares of the company’s stock, valued at $5,107,520.32. The disclosure for this sale can be found here.

Several institutional investors recently made changes to their positions in the stock. Rhumbline Advisers boosted its position in shares of Acceleron Pharma by 7.7% in the fourth quarter. Rhumbline Advisers now owns 20,643 shares of the biopharmaceutical company’s stock valued at $1,007,000 after buying an additional 1,475 shares during the period. California State Teachers Retirement System boosted its position in shares of Acceleron Pharma by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 40,191 shares of the biopharmaceutical company’s stock valued at $1,960,000 after buying an additional 642 shares during the period. Finally, Mutual of America Capital Management LLC boosted its position in shares of Acceleron Pharma by 0.6% in the fourth quarter. Mutual of America Capital Management LLC now owns 44,363 shares of the biopharmaceutical company’s stock valued at $2,163,000 after buying an additional 260 shares during the period.

Acceleron Pharma Inc is a United States-based clinical stage biopharmaceutical company. The Company focuses on discovering and developing therapies to treat a range of diseases. Its therapeutic candidate, luspatercept, is being evaluated in Phase III studies for the treatment of the hematologic diseases myelodysplastic syndromes (MDS) and beta-thalassemia.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.